Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Phase 2

Completed

• Conditions: Corneal Epithelial Disorders
• Interventions: Drug: SJP-0035 Ophthalmic Solution; Drug: Vehicle of SJP-0035 Ophthalmic Solution

• Registration Number: NCT02104388
• Lead Sponsor: Senju Pharmaceutical Co., Ltd.

Brief Summary

The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

Detailed Description

There is currently no product approved for corneal epithelial wound healing. A Phase 1 Study SJP-0035/1-01 was conducted in healthy volunteers to investigate the safety, tolerability, and pharmacokinetic profile of SJP-0035 ophthalmic solution and to determine the appropriate dose to be evaluated in patients with moderate to severe corneal epithelial disorders.

This Phase 2a study is being conducted to evaluate the safety and efficacy of SJP-0035 ophthalmic solution in patients to promote corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

Study Timeline

• Study First Submitted: 2014-03-19
• Study First Submitted QC: 2014-04-03
• Study First Posted: 2014-04-04
• Study Start: 2014-04-08
• Primary Completion: 2015-08-04
• Study Completion: 2015-08-04
• Status Verified: 2021-03
• Disposition First Submitted: 2021-03-23
• Disposition First Submitted QC: 2021-03-25
• Last Update Submitted: 2021-03-25
• Disposition First Posted: 2021-03-29
• Last Update Posted: 2021-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

• Male or female between the ages of 18 and 75 years, inclusive.
• Has moderate to severe superficial punctate keratitis (SPK) and/or corneal erosion in 1 or both eyes.
• Has symptoms caused by corneal epithelial disorders.
• Has not obtained improvement from previous treatment for the SPK or corneal erosion within the last 30 days.
• Is a female of childbearing potential with a negative pregnancy test result at Screening and baseline and agrees to use effective contraception throughout the study or is a postmenopausal woman with a negative pregnancy test result at Screening and baseline.

Exclusion Criteria

• Has any corneal stromal or endothelial abnormalities including an active bacterial or viral ocular infection, bullous keratopathy, or chemical burns or any trauma to the cornea.
• Any active or chronic allergic, bacterial, or viral infection of ocular adnexa and eye structures.
• Had previous ocular/refractive surgery (including laser surgery) within the last 6 months.
• Has used any ocular medication (except mydriatics, stain, and topical anesthesia used for study assessments) within 14 days prior to the first dose of study drug, or who are anticipated to require such medications during the study. Artificial tears may be used up to 72 hours prior to the first dose.
• Is unable to discontinue Restasis. A 28-day washout period prior to the first dose of study drug is required.
• Is a contact lens wearer and cannot discontinue use for the duration of the study.
• Alcohol or drug abuse within the past 6 months.
• Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus test at Screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SJP-0035 Ophthalmic Solution	SJP-0035 Ophthalmic Solution	Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
Vehicle of SJP-0035 Ophthalmic Solution	Vehicle of SJP-0035 Ophthalmic Solution	Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Clearing of corneal fluorescein staining at week 4	measured at Week 4	A patient will be considered a success for clearing of corneal fluorescein staining if their fluorescein staining has disappeared.

Secondary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events as a Measure of Safety.	baseline up to week 18	An Adverse Event is defined as any untoward medical occurrence in a patient enrolled into the study regardless of its causal relationship to study drug.
Changes of subjective symptoms: blurred vision, photophobia and eye irritation	screening up to week 18	100-point assessments are performed for the symptom of blurred vision, photophobia and eye irritation.
Changes of subjective signs: tear stability, conjunctival epithelia, and surface curvature of cornea	screening up to week 18	These changes are measured at every study visit using standard ophthalmology procedures.

Trial Locations

Locations (3)

Senju Investigational Site; 🇺🇸 Norfolk, Virginia, United States

Senju Investigational site; 🇺🇸 Edgewood, Kentucky, United States

Senju Investiational Site; 🇺🇸 Rochester, New York, United States